RenovoRx (NASDAQ:RNXT – Get Free Report) and Nexalin Technology (NASDAQ:NXL – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations.
Insider and Institutional Ownership
3.1% of RenovoRx shares are owned by institutional investors. Comparatively, 0.6% of Nexalin Technology shares are owned by institutional investors. 9.4% of RenovoRx shares are owned by insiders. Comparatively, 16.9% of Nexalin Technology shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Earnings and Valuation
This table compares RenovoRx and Nexalin Technology”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| RenovoRx | $1.98 million | 26.22 | -$11.17 million | ($0.31) | -3.70 |
| Nexalin Technology | $217,155.00 | 4.70 | -$8.22 million | ($14.41) | -0.10 |
Nexalin Technology has lower revenue, but higher earnings than RenovoRx. RenovoRx is trading at a lower price-to-earnings ratio than Nexalin Technology, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares RenovoRx and Nexalin Technology’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| RenovoRx | -621.71% | -135.11% | -101.91% |
| Nexalin Technology | -4,141.94% | -278.24% | -218.42% |
Volatility and Risk
RenovoRx has a beta of 1.12, indicating that its stock price is 12% more volatile than the S&P 500. Comparatively, Nexalin Technology has a beta of 4.31, indicating that its stock price is 331% more volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of recent ratings and recommmendations for RenovoRx and Nexalin Technology, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| RenovoRx | 1 | 0 | 2 | 1 | 2.75 |
| Nexalin Technology | 1 | 1 | 0 | 0 | 1.50 |
RenovoRx currently has a consensus price target of $8.50, indicating a potential upside of 640.42%. Given RenovoRx’s stronger consensus rating and higher probable upside, equities research analysts clearly believe RenovoRx is more favorable than Nexalin Technology.
Summary
RenovoRx beats Nexalin Technology on 11 of the 15 factors compared between the two stocks.
About RenovoRx
RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company has a research collaboration with Imugene Limited to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.
About Nexalin Technology
Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. The company designs and develops Generation 2 and Generation 3, that is in clinical trials for the treatment of substance abuse issues related to opiate, cocaine, alcohol abuse, alzheimer's disease, and dementia. It also licenses and sells Nexalin Device, a non-invasive and undetectable to the human body that can provide relief to its afflicted with mental health issues. The company is based in Houston, Texas.
Receive News & Ratings for RenovoRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RenovoRx and related companies with MarketBeat.com's FREE daily email newsletter.
